Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Bladder Issues Linger in Kids Treated for Ureter Swelling

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Many children surgically treated for a swelling at the end of the ureter have lasting bladder symptoms, such as holding urine or trouble passing stools.

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

News All Time

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Personalized Decision-Making for Patients With Advanced HSPC

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Discharge prescription mismatch versus inpatient dose significantly increased refill rate

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Non-invasive, no-anesthesia lithotripsy recently gained FDA approval

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Study showed immediate improvement in symptoms after intentional retrieval of device at 6 months

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

U.S. study supports findings from a global trial using an external control arm

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Patient in his 60s eventually developed sepsis

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Significantly higher risk of sedative, opioid, cocaine abuse compared with no ED diagnosis

Recommended News For You

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Researchers discover that children who survive cancer have socioeconomic challenges.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Parkinson patient's gait is restored by a spinal cord stimulator.

Recommended Articles For You

Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology 

Age-Related Changes in Platelet Reactivity: Mechanisms, Clinical Implications, and Management Strategies 

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

Connected Oncology Pharmacy Workflow Platforms: Clinical Integration, Safety, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR Natural Killer Cell Therapy Shows Promise in B-Cell Lymphomas

2.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

3.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

4.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

5.

Study confirms link between breast density, higher breast cancer risk

1.

Ferroptosis-Modulating Therapies for Treatment-Resistant Malignancies

2.

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals

3.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

4.

Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship

5.

Drug Exposure During Cytopenia: Clinical Considerations and Evidence-Based Management

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

3.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

5.

Coordinating Supportive Care During Cancer Treatment Delays

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot